Deficiency of trophic factors relating to the survival of oligodendrocytes, combined with direct interactions with the immune system, are favored paradigms that are increasingly implicated in demyelinating diseases of the central nervous system. We and others have previously shown that Sema4A and H-ferritin interact through the T-cell immunoglobulin and mucin domain (Tim-2) receptor in mice. H-ferritin has been identified as the iron delivery protein for oligodendrocytes, whereas Sema4A causes a direct cytotoxic effect. However, the expression of Tim-2 has not been detected in humans. Here, we demonstrate that, similar to rodents, human oligodendrocytes undergo apoptosis when exposed to Sema4A and take up H-ferritin for meeting iron requirements and that these functions are mediated via the Tim-1 receptor. Moreover, we also demonstrate the ability of H-ferritin to block Sema4A-mediated cytotoxicity. Furthermore, we show in a series of pilot studies that Sema4A is detectable in the CSF of multiple sclerosis patients and HIVseropositive persons and can induce oligodendrocyte cell death. Together, these results identify a novel iron uptake mechanism for human oligodendrocytes and a connection between oligodendrocytes and the immune system.
| I N TR ODU C TI ON
Dysregulated myelin production, demyelination, or hypomyelination by oligodendrocytes can lead to a variety of neurological defects, including both motor and cognitive deficits stemming from compromised action potential transmission (Kamm, Uitdehaag, & Polman, 2014) . One of the primary reasons for irregular myelin deposition may revolve around the death of oligodendrocytes, however the causes for this death have yet to be discovered. Though the brain is normally sequestered from the peripheral immune system, demyelinating disorders may arise as a result of inappropriate interactions between oligodendrocytes and immune cells or trophic factors. In multiple sclerosis, a prototypical demyelinating disorder affecting more than 2.5 million people worldwide (Noseworthy, Lucchinetti, Rodriguez, & Weinshenker, 2000) , a number of inflammatory mediators are implicated in demyelination, such as auto-reactive antibodies, infiltrating lymphocytes, and the semaphorin family, suggesting the existence of an oligodendrocyte-immune axis (Leitner, Todorich, Zhang, & Connor, 2015; Okuno, Nakatsuji, & Kumanogoh, 2011; Vadasz & Toubi, 2014) .
Human immunodeficiency virus (HIV) infection is another inflammatory condition that has been associated with progressive loss of brain white matter (WM) and neurocognitive impairment (NCI).
Although combination antiretroviral therapy (cART) can suppress HIV replication below the quantification limit of commercial assays, comorbidities such as NCI occur more frequently in HIV-seropositive (HIV1) adults than in the general population. NCI is associated with smaller volumes of total WM and larger volumes of abnormal WM in the brain (Fennema-Notestine et al., 2013; Jernigan et al., 2011) . These consistently observed WM alterations support the concept that inflammation during immune recovery adversely affects WM integrity. However, the specific molecular mechanisms for these WM changes observed in neuroimaging studies have yet to be defined.
One emerging family of immune-related molecules that have immune-mediated disease properties is the semaphorin family (Vadasz & Toubi, 2014) . Implicated in diseases such as rheumatoid arthritis and asthma, the semaphorin family has been shown to be a key component of immune disease progression (Chapoval, Vadasz, Chapoval, & Toubi, 2016; Koda et al., 2014; Mogie et al., 2013; Wang et al., 2015) . Importantly, previous studies have shown that Sema4A binds to a member of the T-cell immunoglobulin and mucin domain (Tim) family, Tim-2 (Kumanogoh et al., 2002) . Moreover, our laboratory has previously shown that Sema4A causes apoptosis in rodent oligodendrocytes (Leitner et al., 2015) . The ability of Sema4A, a significant immune-mediator expressed and secreted by activated T cells, to induce oligodendrocyte cell death is evidence of a key oligodendrocyte-immune axis. Importantly however, the evidence to this point has yet to be translated to humans, representing scientific and clinical gaps in knowledge.
Another binding partner to Tim-2 is the iron storage protein Hferritin (Hft) (Chen et al., 2005; Han et al., 2011; Todorich, Zhang, Slagle-Webb, Seaman, & Connor, 2008) . Historically, transferrin has been thought to be the obligate iron carrier protein throughout the body. However, previous studies by our laboratory have demonstrated the importance of Hft-mediated delivery of iron to oligodendrocytes through Tim-2 (Todorich, Zhang, & Connor, 2011) . To oligodendrocytes, iron is a critical micronutrient, as iron is a crucial cofactor in the synthesis and proper deposition of myelin (Connor & Menzies, 1996; Todorich, Pasquini, Garcia, Paez, & Connor, 2009 ). Indeed, the most consistent observation in the brain in association with iron deficiency is hypomyelination (Franco et al., 2015) .
Despite the long-standing interest in establishing an oligodendrocyte-immune system axis, translating the rodent findings for Sema4A and Hft to humans remains challenging primarily because Tim-2 expression has not been detected in humans (Kuchroo, Umetsu, DeKruyff, & Freeman, 2003) . The purpose of this study is to demonstrate that Hft is taken up by human oligodendrocytes and Sema4A is toxic to human oligodendrocytes. We hypothesize that Sema4A and Hft both bind to, and are functional at, a shared receptor in humans, likely to be a member of the Tim family. Furthermore, we demonstrate in a series of experiments that Sema4A is found in human CSF and is elevated in human diseases that involve white matter damage, providing an exciting potential clinical link to this pathogenic process. These studies will serve as a crucial impetus for future exploration of Sema4A as a significant clinical factor in demyelinating disorders and H-ferritin as a significant iron delivery protein to human oligodendrocytes.
| M A TE RI A L S A ND M E TH ODS

| Cell culture
We used both primary human oligodendrocytes and the human cell line MO3.13, obtained from Cellutions Biosystems Inc. (Ontario, Canada) in the evaluation of Sema4A cytotoxicity and Hft uptake. MO3.13 cells were originally described as a fusion cell line created by fusing human oligodendrocytes obtained from surgical resection of the temporal lobe with human rhabdomyosarcoma cells (Buntinx et al., 2003; McLaurin, Trudel, Shaw, Antel, & Cashman, 1995) . These cells were cultured as immature oligodendrocytes in DMEM (Gibco) with 10% FBS and 13 penicillin-streptomycin. Importantly, we differentiated these cells into mature oligodendrocytes by removing serum and culturing cells for 3 days in DMEM containing 100 nM 4-b-phorbol 12-myristate 12-acetate (PMA, Sigma) and 1X penicillin-streptomycin (McLaurin et al., 1995) . Mature oligodendrocytes, both primary and MO3.13-derived, express typical differentiated oligodendrocyte markers, such as CC1 and myelin basic protein, while immature cells do not.
Primary human oligodendrocytes were isolated following the protocol outlined by McCarthy and de Vellis (McCarthy & de Vellis, 1980) and Hosokawa (Hosokawa, Klegeris, Maguire, & McGeer, 2003) with minor modifications. Temporal lobe from surgical resection for epilepsy was obtained from two different patients (IRB# 00002914). Briefly, tissues were placed in sterile petri dishes and rinsed with HBSS. Visible blood vessels and meninges were removed and the tissue was chopped into small pieces with a sterile scalpel. Tissue fragments were transferred to a 50 mL tube containing 10 ml 0.25% trypsin (Gibco) and incubated at 378C for 30 min. 10 ml 10% FBS DMEM-F12 (Sigma) was added to the mixture and the whole suspension was centrifuged at 275g for 10 min. After centrifugation, cells were passed through a 100 mm nylon cell strainer and centrifuged again for 10 min at 275g. 
| Cytotoxicity assays
Both MO3.13 and primary human oligodendrocytes were plated at a density of 15,000 cells/well in a 96-well plate format, left to attach overnight. These cells were treated with recombinant Sema4A (AcroBiosystems) or PBS in increasing doses, added directly to the media for 24 hr. MTT (Roche) and LDH (Roche) assays were performed following the manufacturer's instructions. Absorbance was measured at 575 nm or 490 nm using a Spectramax Gemini plate reader (Molecular Devices).
Executioner caspase activity was assayed for using the Caspase-Glo 3/ 7 Assay (Promega), according to the manufacturer's instructions. The pan-caspase inhibitor Z-VAD-FMK (Selleck Chemicals) was used at 50 mM. 
| H-ferritin purification
Recombinant Hft was isolated as previously described (Fisher et al., 2007; Todorich et al., 2011 Todorich et al., , 2008 . Briefly, wild-type BL21 Escherichia coli containing human Hft with a poly-His tag subcloned into pET30a
(1) was grown to produce Hft. Isopropyl-b-D-thio-galactoside (IPTG, Sigma) was used to induce expression. Bacteria were then lysed and Hft protein was purified via nickel column using standard techniques (GE Healthcare Bio-Sciences). Total protein was quantified using bicinchoninic acid assay (BCA, Pierce). Hft identity was verified via western blot (data not shown).
| Immunostaining
Human brain tissue (IRB# 40726) was obtained and sectioned in 5-micron slices. Immunohistochemistry and immunofluorescence was performed as previously described Nandar et al., 2014) . Briefly, slides were deparaffinized and hydrated, performing antigen retrieval with 10mM citrate buffer, pH 6.0. Slides were also To quantify uptake, differentiated MO3.13 cells were plated at 15,000 cells/well in a 96-well plate. Cells were incubated with Hft-QD or Ctrl-QD for 1 hr at 378C. Subsequently, cells were washed three times with 13 DPBS. Fresh media was added and the signal was counted via fluorometer (Molecular Sciences, Excitation: 420 nm, Emission: 620 nm).
For the Luxol fast blue stain, human tissue slides were deparaffinized, rehydrated to 95% ethanol, and stained in 0.1% Luxol fast blue solution overnight at 568C. After incubation, slides were rinsed in distilled H 2 O and differentiated in 0.05% lithium carbonate solution. Furthermore, slides were counterstained in 0.1% crystal violet solution, dehydrated and mounted. Slides were visualized on a light microscope (Leica).
| Western blot
Prior to Western blot, total protein was quantified using bicinchoninic assay (BCA, Pierce). A total of 20 mg protein per lane was loaded onto a denaturing SDS-PAGE gel (BioRad) and subsequently transferred to a nitrocellulose membrane. This membrane was blocked in 5% milk made in Tris-buffered saline and Tween-20 (TBS-T). Blots were probed for Tim-1 (10 mg/ml, R&D Systems), Tim-3 (0.1 mg/ml, R&D Systems) or b-actin (1:3000, Sigma) overnight at 48C. Corresponding secondary antibody conjugated to HRP was used (1:5000, GE Amersham), visualizing bands using ECL reagents (Perkin-Elmer) on an Amersham Imager 600 (GE Amersham) with densitometry analysis using ImageJ.
| Knockdown studies
To knock down Tim-1 and Tim-3 receptor expression, we used Lipofectamine 3000 (ThermoFisher) to perform the transfections (tfx) per the manufacturer's instructions. To confirm receptor knockdown, 1 million differentiated MO3.13 cells were plated in a 6-well plate overnight.
Following this, transfection using either Tim-1, Tim-3, or a scrambled (Scr) pool of siRNA not specific to either Tim proteins (Qiagen) was performed. Cells were lysed in 150 ml RIPA buffer (Sigma), total protein was quantified via BCA, and samples were analyzed via western blot as described above. All other studies were performed in 96-well format, with experiments starting at 24 hr post-transfection. 2,500 ng/well Tim-1 and Tim-3 siRNA (Santa Cruz Biotechnology) were used in the transfections in 6-well, while 100 ng/well siRNA was used in the 96-well transfections.
| Human CSF samples and immunoprecipitation
Thirteen patients undergoing routine diagnostic lumbar puncture for multiple sclerosis evaluation gave informed consent to Dr. Lucassen (IRB# 00002914). Patient diagnosis was obtained after completion of all studies, thus all laboratory and study personnel were blinded to the status of disease during the experiments. Of the 13 patients evaluated, 5 were diagnosed with multiple sclerosis.
Ten CSF samples were also obtained from HIV1 adults who were previously recruited to multicenter studies of the HIV Neurobehavioral Research Center (HNRC) at the University of California-San Diego (see Acknowledgments). All HIV1 study participants were recruited through community outreach and from health care providers, and they provided written informed consent for lumbar puncture as well as comprehensive neurocognitive and neuropsychiatric testing (HNRC study PI, Robert Heaton, IRB# 081375; Heaton et al., 2011) . For the analyses reported here, only samples from HIV1 persons on cART, who did not have AIDS-defining conditions, hepatitis C virus co-infection, or a history of substance abuse or syphilis, were selected for study. In addition,
all individuals had a diagnosis of mild or moderately severe NCI, as defined elsewhere (Kallianpur et al., 2016) . CSF Sema4A content was examined using a Sema4A-specific ELISA (Biomatik), following the manufacturer's instructions. Total CSF protein was quantified via BCA. Utilizing Dynabeads Protein A (Invitrogen), 10 mg anti-Sema4A antibody (Abcam) was cross-linked to the magnetic beads using BS3 (Invitrogen). Patient CSF was added to the magnetic bead-antibody solution and incubated at room temperature with gentle agitation for 4 hr. Samples were washed and eluted following the manufacturer's instructions. Identity of the Sema4A product was verified via western blot as described above (data not shown).
| Statistical analysis
All statistical analyses were performed using GraphPad Prism 4 Software (GraphPad Software, Inc.). Data from three independent biological replicates were averaged and are expressed as the mean 6 SD. Twoway ANOVA with Bonferroni post-hoc analysis, unpaired t test, Dunnett's or Mann-Whitney tests were used where appropriate to evaluate statistical significance. A p value <.05 was considered significant.
| Experimental design
Study investigators were blinded to the disease/control status and diagnoses pertaining to CSF samples through a third-party coding mechanism. Patient samples were given a unique coded number while studies were being performed. Only after the studies were finished and the data analyzed were diagnoses revealed to investigators.
| RE S U L TS
The primary cultures were stained with markers for mature oligodendrocytes (CC1 and MBP), astrocytes (GFAP) and microglial cells (Iba1) to identify the cell types present. Only CC1 and MBP immunostained cells were observed. Moreover, these cells also immunostained for Tim-1 (Figure 1 ). The positive staining and the morphological appearance of the cells in culture were consistent with oligodendrocytes.
| Sema4A induces apoptosis in human oligodendrocytes
In order to demonstrate the physiological effects of Sema4A on human oligodendrocytes, we treated the oligodendrocyte cell line MO3.13 as well as primary human oligodendrocytes with increasing doses of Sema4A (Figure 2) . In this study, we used primary human oligodendrocytes in addition to the MO3.13 cell line in order to demonstrate similarity in functional response between the two cell types. Similar to our previous studies in rodents (Leitner et al., 2015) and in the mature MO3.13 cell line, Sema4A produced a dose-dependent cytotoxic effect measured by MTT and LDH assay, in both the cell line and primary cells (Figure 2a-c) . The cytotoxicity in the MO3.13 cells was only seen in mature cells. We next wanted to study the mechanism of cell death.
Given the relatively rapid timeframe of cytotoxicity, we hypothesized that Sema4A induced apoptosis. We found that treatment with Sema4A significantly increases both the amount of Annexin V binding to phosphatidylserine, a marker for early apoptosis, as well as total caspase 3 and 7 activity (Figures 2d,e ).
| H-ferritin is taken up by human oligodendrocytes
Next, we investigated the ability of both the mature MO3.13 cell line and primary human mature oligodendrocytes to take up Hft (Figure 3 ).
For this study, we conjugated red fluorescent quantum dots (QD) to Hft and incubated Hft-QD with the cells. We used a PBS-QD (Ctrl-QD) mixture to control for the random uptake of the QD itself, and did not observe any uptake (Figure 3a) . In sharp contrast however, when Hft-QD was incubated with mature MO3.13 and primary oligodendrocytes, a robust uptake was observed (Figure 3b,c) . When quantified, Hft-QD uptake (402.95 RFU) was significantly higher than Ctrl-QD uptake (47.40 RFU, p value 5 .0022, Mann-Whitney test).
| Human oligodendrocytes express Tim-1
To investigate the role of Tim-1 on the effects by Sema4A and Hft, we first determined the cellular localization of Tim-1 protein expression in 3.4 | Tim-1, but not Tim-3, knockdown results in decreased Sema4A cytotoxicity and H-ferritin uptake Previous studies by our laboratory and others have demonstrated binding of both Sema4A and Hft to Tim-2 (Kumanogoh et al., 2002; Todorich et al., 2008) . As previously stated, the gene for Tim-2 has yet to be detected in humans, however candidates for the Hft and Sema4A receptor are likely the other members of the Tim family found in humans, Tim-1 or Tim-3. We chose these receptors based on sequential and structural homology, respectively. Tim-4, the remaining member of the Tim family in humans, was not examined in this study due to a lack of either sequential or structural homology to murine Tim-2 and a lack of expression outside the immune system (Freeman, Casasnovas, Umetsu, & DeKruyff, 2010; Santiago et al., 2007) . To assess the possible role of these receptors in Sema4A cytotoxicity, we transfected mature MO3.13 cells with siRNA to knock down the expression of Tim-1 or Tim-3 (Figure 5a,c) . As a negative control, we transfected mature MO3.13 cells with a pool of scrambled siRNA. We demonstrate that at 24 hr post-transfection, the protein expression for both Tim-1 and Tim-3 was reduced to roughly 25% (Figure 5b,d) . Following this transfection, we treated these cells with Sema4A in increasing doses (Figure 5e ). When Tim-3 was knocked down, there was no change in the level of cytotoxicity, compared with the untransfected or scrambled siRNA transfected groups. However, there was a significant rescue of Sema4A cytotoxicity after Tim-1 knockdown.
Given the robust effect of Tim-1 knockdown on Sema4A cytotoxicity, we next examined the role of Tim-1 in Hft uptake by human oligodendrocytes. When Tim-1 expression was knocked down, there was a noticeable decrease in the level of Hft taken up (Figure 6a ). However, when the control scrambled siRNA was transfected instead, there was no decline in level of Hft-QD in the cell (Figure 6b ). This effect was quantified, demonstrating that after Tim-1 siRNA transfection, uptake of Hft-QD was significantly decreased, whereas Tim-3 siRNA transfection had no noticeable effect compared with the scrambled transfection (Figure 6c ).
| H-ferritin can block Sema4A cytotoxicity
The siRNA studies indicate that Sema4A and Hft share and function through the Tim-1 receptor. To assess the role of Hft in Sema4A cytotoxicity, we treated human oligodendrocytes with both Sema4A and Hft concurrently (Figure 7a ). When Sema4A was added alone, there was a similar dose-dependent decrease in cell viability, as seen previously. When Hft was added alone, there was no significant effect on cell viability until the higher concentrations. When we added Hft at a constant dose of 50 mg/ ml and Sema4A at increasing doses concurrently (Sema4A 1 Hft group), there was a rescue effect seen, returning cell viability levels back to control. To corroborate this effect, we used the pan-caspase inhibitor Z-VAD-FMK in order to block the apoptotic effect exerted by Sema4A (Figure   7b ). At low doses of Sema4A, this apoptotic effect was completely inhibited. However, at high concentrations, the 50 mM concentration of Z-VAD-FMK was unable to fully reverse this effect.
| Sema4A from CSF is cytotoxic to oligodendrocytes
Next, we examined the levels and cytotoxic profile of Sema4A in CSF from five patients with multiple sclerosis who underwent routine diagnostic lumbar puncture and from 10 HIV1 adults who consented to this procedure as part of previously conducted HIV studies. We first used a Sema4A-specific ELISA on all CSF samples in order to determine levels of Sema4A (Figure 8a) . From this experiment, we demonstrated that Sema4A levels are higher in patients diagnosed with multiple sclerosis (86.37 6 29.99 ng/ml) and in HIV1 individuals (68.50 6 10.04 ng/ml) compared with HIV-negative, non-multiple sclerosis controls (7.76 6 2.23 ng/ml; p < .001). As mentioned previously, multiple sclerosis patient diagnosis was obtained after all studies were finished, thus all experiments were performed blinded to disease status. We then used a Dynabeads platform coupled to an anti-Sema4A antibody to immunoprecipitate Sema4A from the CSF, resulting in three groups: complete CSF, CSF without Sema4A, and the immunoprecipitated Sema4A. The samples representing these groups were then applied to mature MO3.13 cells and cytotoxicity assessed by LDH assay. Exposing the cells to the immunoprecipitated solution resulted in significant cell death, as compared with the control condition (Figure 8b) . Furthermore, the complete CSF mixture was cytotoxic in increasing doses only when Sema4A was present while CSF that had Sema4A levels decreased by immunoprecipitation was less cytotoxic (Figure 8c ). These results are also reflected in the larger pool of samples from HIV1 individuals (Figure 8d,e ). These data demonstrate that when mature MO3.13 cells are treated with the CSF from HIV1 individuals, there is cell death. When Sema4A was immunoprecipitated from these samples, the cytotoxicity profile was greatly reduced (Figure 8d ). Next we examined individual differences in cytotoxicity between CSF with Sema4A and CSF minus Sema4A, finding a decrease in cytotoxicity in 8 out of 10 samples (Figure 8e ).
| D ISC USSION
The aim of this study was to expand our earlier findings for Sema4A and Hft from animals to humans and find the receptor mediating the (e) Tim-1, but not Tim-3, knockdown results in a protection from Sema4A-mediated cytotoxicity. Means were evaluated for statistical significance using two-way ANOVA with Bonferroni's post hoc comparisons. Graphs represent means of three biological replicates 6 SD. *p < .05, **p < .01, ***p < .001 where * refers to comparisons between the experimental group and the 1Sema4A and 1Tim-1 tfx condition interaction of Sema4A and Hft with human oligodendrocytes. Moreover, we demonstrated the presence of Sema4A in human CSF and that the Sema4A in this CSF is cytotoxic to oligodendrocytes. In a cell culture model utilizing both primary human oligodendrocytes and an oligodendrocyte cell line, we have demonstrated a novel role for Sema4A and Hft in humans and evidence for an oligodendrocyteimmune axis that appears informative to demyelinating diseases pathogenesis. Moreover, we provide evidence that Tim-1 is present on human oligodendrocytes in the CNS and is the receptor that mediates these effects.
Building upon our previous studies, we demonstrate that Sema4A is cytotoxic to human oligodendrocytes and is a significant immune factor in CSF that causes apoptosis in oligodendrocytes. That Sema4A induces apoptosis and that this process can be blocked using a pancaspase inhibitor implies an intracellular signaling cascade leading to executioner caspase activity. Interestingly, immature oligodendrocytes in this study are unaffected by Sema4A treatment; whereas we previously reported the immature MO3.13 cells were less sensitive to Sema4A we did observe cytotoxicity at high doses in that study. This difference in sensitivity to the high doses of Sema4A appear related to cells of higher passage number being more sensitive. Previous studies of oligodendrocytes have demonstrated that while transferrin receptor is expressed by immature oligodendrocytes, it is absent in mature myelinating oligodendrocytes and adult human brain WM (Bean et al., 2013; Cheng et al., 2015; Hulet, Menzies, & Connor, 2002) . This finding corroborates our earlier studies demonstrating ferritin binding in WM tracts in rodents and humans (Hulet, Hess, et al., 1999; Hulet, Heyliger, Powers, & Connor, 2000; Hulet et al., 2002) and other studies demonstrating ferritin binding to oligodendrocytes (Chen et al., 2005; Han et al., 2011; Todorich et al., 2008) . The current data, combined with our previous reports, suggest that Tim-1 is expressed on oligodendrocytes during differentiation and by mature oligodendrocytes. This finding is possibly relevant to the presence of transferrin-receptorpositive oligodendrocyte progenitor cells (OPCs), but no ferritin binding, around multiple sclerosis lesions (Connor & Menzies, 1996; Hulet et al., 2000; Wolswijk, 2000) and suggests that as cells in the periplaque region attempt to mature they would become vulnerable to | 1325 (Todorich et al., 2009 (Todorich et al., , 2011 . To date, the human receptor for Hft on oligodendrocytes had not been identified. Torti and colleagues have shown that transferrin receptor 1 (TfR1) can bind to H-ferritin (Li et al., 2010) , but the binding was not saturable, unlike the binding of Hft by Tim-2 (Todorich et al., 2008) . Moreover, Hft binding to TfR1 inadequately explains iron uptake in oligodendrocytes in adult human WM which lack TfR1 expression . Thus, it is unlikely that TfR1 functions as the receptor for Hft on oligodendrocytes. In this study, we demonstrate using siRNA that human oligodendrocytes take up Hft and that this uptake is mediated through Tim-1.
The other candidate in the Tim family that was analyzed was Tim-3 due to the respective sequential and structural homology between Tim-2 and human Tim-1/3 (Kuchroo et al., 2003) . Tim-4 was not considered a viable candidate for study because it is exclusively expressed on antigen-presenting cells and thus was not our focus (Freeman et al., 2010) .
Though both Sema4A and Hft function through Tim-1, the cellular effects these ligands exert differ greatly. One potential explanation for these differences may be that Sema4A may act as an inhibitor of Hft uptake. As iron is an essential micronutrient to the brain, and oligodendrocytes in particular, the ability of Sema4A to block iron uptake through Hft may contribute to the cell death observed in this study.
This may further explain why immature oligodendrocytes are unaffected by Sema4A, as their primary method of iron acquisition is through transferrin, rather than Hft, and thus do not share a receptor with Sema4A. The cytotoxic effect of Hft at higher doses was not unexpected, as it is well-documented that too much iron can also cause cytotoxicity through free radicals and oxidative stress. Though we explored the role of apoptosis in Sema4A mediated cytotoxicity, we fully appreciate that apoptosis and necrosis are not mutually exclusive and that by depriving these cells of iron, both necrosis and apoptosis pathways of cell death may be induced. An alternative explanation for the differing effects of Hft and Sema4A binding may stem from Tim-1 splice variants, resulting in Tim-1a and Tim-1b (Bailly et al., 2002) .
Importantly, Tim-1b has the intracellular C-terminal tyrosine phosphorylation motif QAEDNIY while Tim-1a does not, suggesting the ability for Tim-1b to induce intracellular signaling (Bailly et al., 2002) . These findings suggest that differential binding of Hft and Sema4A to either Tim-1a or Tim-1b may lead to different downstream effects. Finally, murine Tim-1 and Tim-2 have been shown to form functioning homodimers, suggesting a similar role for human Tim receptors (Santiago et al., 2007) . Though the siRNA used in these studies does not discriminate between the Tim-1 splice variants, studies to further explore the mechanism of the different functions of these variants are in progress.
Our study shows significant elevation of Sema4A in the CSF of patients with multiple sclerosis and HIV1 individuals, the first such demonstration and a finding with potentially exciting clinical implications. The Sema4A isolated from this CSF directly causes oligodendrocyte death, providing a potential biomarker of multiple sclerosis disease activity. Although we cannot rule out a contribution from other potentially cytotoxic factors, it is clear from the immunoprecipitation studies that Sema4A is a significant contributor to oligodendrocyte death. Previous studies have linked serum Sema4A levels to multiple sclerosis and therapeutic response (Nakatsuji et al., 2012) . For example, interferon-beta treatment is ineffective in relapsing-remitting multiple sclerosis patients, who have both pro-inflammatory T-helper 17 (Th17) cell skewing (Zhou, Chong, & Littman, 2009 ) and elevated serum Sema4A levels (Koda et al., 2014; Nakatsuji et al., 2012) . Moreover, inactivation of Sema4A and Tim-2 signaling decreased the clinical symptoms and histopathological severity of experimental allergic encephalomyelitis (EAE), the mouse model for multiple sclerosis (Kumanogoh et al., 2002) . While the source of Sema4A in the CSF examined has yet to be determined, previous findings by our lab have also demonstrated upregulation of Sema4A after microglial activation, providing more evidence for brain immune activation (Leitner et al., 2015) . It is also known that Sema4A is present on dendritic cells and CD41 Th1 cell (Ito & Kumanogoh, 2016) . Further studies will examine the exact source of Sema4A found in the brain. The findings from this study require replication using a larger sample size, but it is clear even from the small dataset herein that despite variation in the individual CSF responses, there is a consistent trend that indicates Sema4A is FIG URE 7 Sema4A cytotoxicity is blocked by H-ferritin or caspase inhibition. (a) H-ferritin can block Sema4A cytotoxicity, when compared with Sema4A alone or Hft alone conditions. Absorbance is quantified relative to a PBS control condition (not shown). In the Sema4A 1 Hft condition, Hft concentration was added at a constant 50 mg/ml while Sema4A was added in increasing doses as labeled. (b) Z-VAD-FMK, a pan-caspase inhibitor, can block Sema4A cytotoxicity. This rescue effect is diminished at high concentrations of Sema4A. Absorbance is quantified relative to the untreated control. Means were evaluated for statistical significance using twoway ANOVA with Bonferroni's post hoc comparisons. Values represent means of three biological replicates 6 SD. *p < .05, ***p < .001 cytotoxic and removal of Sema4A decreases this cytotoxicity. One potential explanation for the individual variability is the Hft to Sema4A ratio present in the CSF. We demonstrated in the cell culture model that Hft can limit Sema4A-mediated cytotoxicity. Hft is not only present in the human CSF (Patton et al., 2017) , but in support of the notion that it could impact cytotoxicity has been shown to be protective in HIV persons. Taken together, these findings indicate a role for Sema4A in the pathophysiology of demyelination and a clear relationship between Tim-1, iron uptake in oligodendrocytes, and the immune system.
In addition, this study is the first to suggest a role for Sema4A in demyelinating neurological diseases other than multiple sclerosis, in particular, HIV-associated NCI (Liu, Xu, Liu, & Xiong, 2016) . Damage to WM is detected early in the course of HIV infection (Ragin et al., 2015) and is clearly related to the duration and severity of immunosuppression, as reflected by a lower CD41 T-cell nadir, but several studies suggest that immune recovery may also play an independent role in the evolution of brain abnormalities and NCI (Fennema-Notestine et al., 2013) . Specifically, reduced WM integrity on neuroimaging is associated with higher current and lower nadir CD4 1 T-cell counts (Fennema-Notestine et al., 2013; Gongvatana et al., 2013; Jernigan et al., 2011; Seider et al., 2016; Zhu et al., 2013) . Fennema-Notestine et al. showed that HIV1 adults experienced significant loss of total cerebral WM volume, alongside increases in abnormal WM volume. These consistently observed WM alterations, which may progress as the CD41 T-cell count recovers during cART, could potentially contribute to NCI. These studies suggest that inflammation during immune recovery on cART adversely affects cerebral WM integrity, but other mechanisms of WM damage have not been sufficiently investigated; our findings implicate increased levels of Sema4A as another possible mechanism, requiring further study. Additional studies further investigating a role for Sema4A in HIV neuropathogenesis are currently underway.
Overall, the data presented in this study provide evidence for a novel neuro-immune axis between oligodendrocytes in the brain and the immune trophic factor Sema4A. Importantly, these studies have elucidated a novel and significant receptor for Sema4A and Hft on oligodendrocytes. In preliminary studies, we also provide exciting 
